• No results found

combination chemotherapy

Combination Chemotherapy for Small Cell Lung Cancer

Combination Chemotherapy for Small Cell Lung Cancer

... Combination Chemotherapy for Small Cell Lung Cancer ORIGINAL ARTICLE Combination Chemotherapy for Small Cell Lung Cancer A W Sufarlan, MRCP B M Z Zainudin, MRCP Respiratory Unit, Department of Medicin[.] ...

5

A review of topotecan in combination chemotherapy for advanced cervical cancer

A review of topotecan in combination chemotherapy for advanced cervical cancer

... cisplatin chemotherapy and radiation have shown high response rates with improvements in durable remissions and overall ...of combination chemotherapy and tolerability of patients are other factors ...

6

Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature

Metastatic ameloblastoma responding to combination chemotherapy: case report and review of the literature

... methotrexate 5-fluorouracil therapy in a patient with lung metastases that occurred nine years after initial therapy. He noticed that the functional outcome was good although no objective response was seen [11]. Ramadas ...

5

Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

Outcome of Combination Chemotherapy with Docetaxel, Estramustine Phosphate, and Carboplatin after Docetaxel and Prednisolone Therapy in Patients with Metastatic Castration Resistant Prostate Cancer

... docetaxel-based chemotherapy, Nakabayashi et ...of combination chemotherapy with TEC as second-line therapy, Sella et ...of combination paclitaxel, carboplatin, and EMP in 15 patients ...

9

Primary systemic chemotherapy in locally advanced breast cancer- taxane versus non-taxane combination chemotherapy schedule

Primary systemic chemotherapy in locally advanced breast cancer- taxane versus non-taxane combination chemotherapy schedule

... Our study has some limitations. Even though it is a prospective study, it is not a randomized study. But still, from the available data from this study and the data from several randomized trials it is better to advise a ...

6

Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy

Targeting Cancer using Polymeric Nanoparticle mediated Combination Chemotherapy

... treatment, chemotherapy shows inadequacy in its methodology due to imminent side-effects and acquired drug-resistance by cancer ...in combination providing promising results. Combination therapy has ...

6

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

... Summary Two hundred and eighty-four patients with advanced Hodgkin's disease HD stage II with poor prognostic features and stage III/IV have been treated with the ChlVPP combination chem[r] ...

7

Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis

Comparison of single agent versus combined chemotherapy in previously treated patients with advanced urothelial carcinoma: a meta-analysis

... other chemotherapy drugs as sal- vage treatment for advanced UC patients, resulting in a larger sample size (1,685 versus 370 ...with combination chemotherapy versus single ...

9

Gemcitabine and Carboplatin in Inoperable, Loco-Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute

Gemcitabine and Carboplatin in Inoperable, Loco- Regionally Advanced and Metastatic Gallbladder Cancer- A Study from Northern Indian Cancer Institute

... carboplatin combination chemotherapy in the present study suggest the potential role of this combination in the management of advanced inoperable ...carboplatin combination chemotherapy ...

7

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

The National Institute for Health and Care Excellence (NICE) Guidance on Bladder Cancer; a Step in the Right Direction?

... Bladder cancer is the 7 th commonest cancer in the UK accounting for 5,369 deaths in 2014 [1]. Over the last decade, despite improvements in other cancers, bladder cancer survival has remained static [2, 3]. Treatment of ...

10

A seven year disease free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report

A seven year disease free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report

... Moreover, chemotherapy, radiotherapy, or a combi- nation of both have been considered as palliative therapy in inoperable ...and combination chemotherapy studies have been performed for ...

5

Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes

Clinical significance of locoregional and systemic treatment in operable high-risk breast cancer patients with more than four positive axillary lymph nodes

... anthracycline–taxane combination chemotherapy compared to cyclophosphamide/methotrexate/fluorouracil chemotherapy, our findings showed benefits on DFS and OS for appropriate local treatments, ...

9

ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION

ANTI-MÜLLERIAN HORMONE AND INHIBIN-B LEVEL PROFILE IN CERVICAL CANCER PATIENTS TREATED WITH PACLITAXEL AND CISPLATIN COMBINATION

... the combination chemotherapy on serum levels of Anti-Mullerian Hormone (AMH) and inhibin ...Paclitaxel–Cisplatin chemotherapy with ...Paclitaxel-Cisplatin chemotherapy in each series of ...

5

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy  for stage III/IV non-small-cell lung cancer

Clinical comparative investigation of efficacy and toxicity of cisplatin plus gemcitabine or plus Abraxane as first-line chemotherapy for stage III/IV non-small-cell lung cancer

... of chemotherapy has increased significantly and the remission rate has reached up to 40% because of the continuous increase in new effective anticancer drugs and new schemes in both quantity and ...quality. ...

6

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis

... neoadjuvant chemotherapy (NAC) has been proposed to improve the pathologic complete response (pCR) rate, although there are conflicting views about its efficacy and ...

9

A META-ANALYSIS STUDY OF POLYCHEMOTHERAPY VERSUS MONOCHEMOTHERAPY IN PATIENTS OF METASTATIC BREAST CANCER

A META-ANALYSIS STUDY OF POLYCHEMOTHERAPY VERSUS MONOCHEMOTHERAPY IN PATIENTS OF METASTATIC BREAST CANCER

... other types of treatments. Although there is no overwhelming clinical evidence in favour of using it, it is widely accepted that women with metastatic disease should receive some form of combinational chemotherapy ...

10

Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer

<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>

... destabilize DNA (alkylating agents), inhibition of DNA replication (antimetabolites), chemical damaging of DNA, inhibition of the function of crucial enzymes required for DNA synthesis (topoisomerase inhibitors), or ...

13

Original Article Bortezomib in combination with chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients: single-center study results

Original Article Bortezomib in combination with chemotherapy and autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma patients: single-center study results

... Among the 137 patients, 35 cases are male and 20 of female. Median age was 50 (33~65) years old, 30 of IgG, 16 of IgA, 4 of IgD, 4 of light chain and 1 of oligosecretory secretion. 51 in III phase and 4 in II phase in ...

8

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

... in combination with carboplatin and paclitaxel, and for the treatment of first recurrence of platinum-sensitive ovarian cancer in combination with carboplatin and ...standard chemotherapy in four ...

13

Gefitinib Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis

Gefitinib Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis

... plus chemotherapy and Cetuximab plus chemotherapy in treating advanced NSCLC without head-to-head studies published, expecting to provide assistance for clinical purposes ...

10

Show all 10000 documents...

Related subjects